PennyMac Mortgage Investment Trust Announces Date for Release of Third Quarter 2026 Results
Get Alerts PMT Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 13.4%
EPS Growth %: -45.5%
Join SI Premium – FREE
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- PennyMac Mortgage Investment Trust (NYSE: PMT) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. Management will host a conference call and live audio webcast at 6:00 p.m. Eastern Time to review the results.
The release, webcast, and accompanying materials will be available online at pmt.pennymac.com. A replay of the webcast will be available shortly after its conclusion.
Individuals who are unable to access the website but would like to receive a copy of the materials should contact our Investor Relations department at 818.224.7028.
About PennyMac Mortgage Investment Trust
PennyMac Mortgage Investment Trust is a mortgage real estate investment trust (REIT) that invests primarily in residential mortgage loans and mortgage-related assets. PMT is externally managed by PNMAC Capital Management, LLC, a wholly-owned subsidiary of PennyMac Financial Services, Inc. (NYSE: PFSI). Additional information about PennyMac Mortgage Investment Trust is available at pmt.pennymac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261007219876/en/
Media Contact
Kristyn Clark
[email protected]
805.395.9943
Investors
Isaac Garden
[email protected]
818.224.7028
Source: PennyMac Mortgage Investment Trust
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- Crypto News: Bitcoin and XRP Face Oil’s $117 Close as Remittix Invites Earn Testers With Weekly Payouts
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share